{"nctId":"NCT01628393","briefTitle":"Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients","startDateStruct":{"date":"2012-09-18","type":"ACTUAL"},"conditions":["Relapsing Multiple Sclerosis"],"count":258,"armGroups":[{"label":"Ozanimod 0.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Ozanimod"]},{"label":"Ozanimod 1 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Ozanimod"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Ozanimod","Drug: Placebo"]}],"interventions":[{"name":"Ozanimod","otherNames":["RPC1063","Zeposia®"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria\n* Expanded Disability Status Scale (EDSS) score between 0 and 5.0 at Baseline\n\nExclusion Criteria:\n\n* Secondary or primary progressive multiple sclerosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Total Number of Gadolinium-Enhancing (GdE) Lesions Assessed on Brain Magnetic Resonance Imaging (MRI) From Week 12 to Week 24","description":"The cumulative number of total GdE lesions on MRI from Week 12 to Week 24. MRI scans were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"29.87"},{"groupId":"OG001","value":"1.9","spread":"4.77"},{"groupId":"OG002","value":"1.5","spread":"3.44"}]}]}]},{"type":"SECONDARY","title":"The Number of Gadolinium-Enhancing Lesions on Brain MRI Scan at Week 24","description":"MRI scans were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"9.81"},{"groupId":"OG001","value":"0.4","spread":"1.27"},{"groupId":"OG002","value":"0.2","spread":"0.59"}]}]}]},{"type":"SECONDARY","title":"The Total Number of New or Enlarging Hyperintense T2-Weighted Brain MRI Lesions From Week 12 to Week 24","description":"The cumulative number of new or enlarging hyperintense T2-weighted brain MRI lesions from Week 12 to Week 24.\n\nMRI scans were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"20.87"},{"groupId":"OG001","value":"1.4","spread":"3.21"},{"groupId":"OG002","value":"0.8","spread":"1.86"}]}]}]},{"type":"SECONDARY","title":"Adjusted Annualized Relapse Rate (ARR) at Week 24","description":"A relapse was defined as new or worsening neurological symptoms attributable to MS and preceded by a relatively stable or improving neurological state for at least 30 days. Symptoms must have persisted for \\> 24 hours and not be attributable to confounding clinical factors. Relapses were confirmed when accompanied by objective neurological worsening based on examination by the blinded evaluator, consistent with an increase of ≥ 0.5 on the overall EDSS score relative to the most recent EDSS assessment, or 2 points on one of the functional system scale scores, or 1 point on ≥ two functional system scale scores.\n\nRelapse rate was calculated as the total number of confirmed relapses divided by the total number of days in the study \\* 365.\n\nARR was based on a Poisson regression model, adjusted for region, relapses within 24 months before the study, and presence of gadolinium-enhancing lesions at Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"0.35","spread":null},{"groupId":"OG002","value":"0.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Treatment Period","description":"An adverse event (AE) is any untoward medical occurrence that does not necessarily have a causal relationship with the investigational product (IP), including an abnormal laboratory finding, symptom or disease temporally associated with the use of an IP whether or not considered related to the IP. Serious AEs were events that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, were congenital abnormalities/birth defects, or important medical events which may have required medical intervention to prevent one of the above outcomes.\n\nThe investigator assessed the severity of AEs as mild, moderate, or severe, and the relationship of each AE to treatment as unrelated, unlikely, possible, probable, or related based on timing and other known factors such as clinical state, environment, or other therapies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAE) During Ozanimod Exposure","description":"AEs are reported from the start of the placebo-controlled period for participants originally assigned to ozanimod and from the start of the extension period for participants who switched to ozanimod after Week 24.\n\nSerious AEs were events that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, were congenital abnormalities/birth defects, or important medical events which may have required medical intervention to prevent one of the above outcomes.\n\nThe investigator assessed the severity of AEs as mild, moderate, or severe, and the relationship of each AE to treatment based on timing and other known factors such as clinical state, environment, or other therapies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"73","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"POST_HOC","title":"Number of Gadolinium-Enhancing (GdE) Lesions During the Extension Period","description":"MRI scans were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"13.02"},{"groupId":"OG001","value":"0.4","spread":"1.28"},{"groupId":"OG002","value":"1.9","spread":"5.93"},{"groupId":"OG003","value":"0.2","spread":"0.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"2.63"},{"groupId":"OG001","value":"0.4","spread":"1.30"},{"groupId":"OG002","value":"0.4","spread":"1.35"},{"groupId":"OG003","value":"0.2","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.95"},{"groupId":"OG001","value":"0.4","spread":"1.41"},{"groupId":"OG002","value":"0.1","spread":"0.28"},{"groupId":"OG003","value":"0.2","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.46"},{"groupId":"OG001","value":"0.4","spread":"1.49"},{"groupId":"OG002","value":"0.1","spread":"0.37"},{"groupId":"OG003","value":"0.2","spread":"0.51"}]}]}]},{"type":"POST_HOC","title":"Total Number of New or Enlarging Hyperintense T2-Weighted Brain MRI Lesions In the Extension Period","description":"The cumulative number of new or enlarging hyperintense T2-weighted brain MRI lesions from Week 12 to Week 24 in the placebo controlled period (reference) and during the first and second years of the extension period.\n\nMRI scans were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"3.58"},{"groupId":"OG001","value":"1.4","spread":"0.35"},{"groupId":"OG002","value":"7.3","spread":"3.07"},{"groupId":"OG003","value":"0.9","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"1.99"},{"groupId":"OG001","value":"2.8","spread":"0.72"},{"groupId":"OG002","value":"1.5","spread":"0.39"},{"groupId":"OG003","value":"1.9","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.31"},{"groupId":"OG001","value":"2.3","spread":"0.61"},{"groupId":"OG002","value":"1.9","spread":"0.48"},{"groupId":"OG003","value":"0.7","spread":"0.16"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":88},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Headache","Alanine Aminotransferase Increased","Back Pain"]}}}